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SummARy – Churg-Strauss syndrome (CSS) is a small-vessel necrotizing vasculitis typically 
characterized by asthma, lung infiltrates, extravascular necrotizing granulomas and hypereosinop-
hilia. Cardiac disease is a major contributor to disease-related death in CSS. we describe a 38-ye-
ar-old man with late-onset asthma, allergic rhinosinusitis, and high extravascular and peripheral 
blood eosinophilia, who presented with migratory pulmonary infiltrates and acute myopericarditis. 
Antineutrophilic cytoplasmic antibodies (AnCA) were negative. early therapy with medium-dose 
methylprednisolone led to resolution of the pericardial effusion and significant clinical improve-
ment. in the present case report, the importance of early recognition of CSS in patients with asthma 
and peripheral eosinophilia is discussed. Cardiac magnetic resonance imaging, besides electro- and 
echocardiography, may be helpful in early detection of cardiac involvement in CSS, enabling appro-
priate treatment aimed to prevent further disease progression and potentially fatal consequences.
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Introduction
Churg-Strauss syndrome (CSS) is a small-vessel 
necrotizing vasculitis typically characterized by asth-
ma, lung infiltrates, extravascular necrotizing granu-
lomas and hypereosinophilia1. The cause of CSS is 
unknown. The presence of marked tissue and blood 
eosinophilia, as well as secretory products of eosino-
phils in blood and tissues implicate a pathogenetic role 
of eosinophil granulocytes. Although the mechanisms 
involved in eosinophil activation in CSS have not been 
elucidated, recent studies suggest the possible role of 
t lymphocytes secreting eosinophil-activating cytok-
ines2. CSS is a rare disease. The estimated annual in-
cidence of CSS is 1-3 per million, although epidemio-
logical data differ among reports. watts et al. report 
on the annual incidence of CSS in norwich, uK, of 
2.7-3.1 per million3. This was significantly higher than 
in two other regions. The annual incidence of CSS in 
tromsø, norway, and lugo, Spain, is reported as 0.5 
and 0.9 per million, respectively4. in a study aimed to 
estimate the incidence of CSS in asthmatics, harrold 
et al. analyzed a population of 184,667 asthma drug 
users contributing 606,184 person-years of exposure 
and report on the overall incidence as high as 34.6 
per million person-years, with no sex and age differ-
ences5. 
Clinical presentation of CSS occurs in three usu-
ally sequential stages. The initial, prodromal stage is 
characterized by allergic inflammation of the nose 
(nasal polyposis), sinuses, skin and lungs. patients are 
often diagnosed with late-onset asthma during this 
stage. The second stage is characterized by periph-
eral blood eosinophilia and eosinophilic infiltration of 
multiple organs. in the third stage, systemic symp-
toms (e.g., fever, malaise, weight loss, fatigue) due 
to potentially life-threatening systemic vasculitis are 
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common. Although the skin and the lungs are among 
the most often affected organs, pathological findings 
of necrotizing eosinophilic vasculitis could be demon-
strated in nearly all major organ systems6.
The diagnosis of CSS is based on clinical criteria, 
routine laboratory tests and biopsy, if possible. Clas-
sification criteria of the American College of Rheu-
matology include asthma, eosinophilia of >10% in 
peripheral blood, paranasal sinusitis, pulmonary in-
filtrates, sometimes transient, histologic evidence of 
vasculitis with extravascular eosinophils, and monon-
euritis multiplex or polyneuropathy7. The presence of 
at least four of these criteria yields a sensitivity of 85% 
and specificity of 99.7%. Beside these criteria, in some 
patients the early diagnosis of CSS may be difficult, 
mostly due to significant differences in its severity. 
in addition, the stages of CSS do not necessarily fol-
low one another consecutively, and the time interval 
between them may vary greatly. The histologic dif-
ferential diagnosis of CSS in the lung includes disor-
ders associated with prominent eosinophilic infiltrates 
or a combination of eosinophils and granulomatous 
inflammation (e.g., eosinophilic pneumonia, hypere-
osinophilic syndrome, allergic bronchopulmonary 
aspergillosis, wegener granulomatosis)8. The progno-
sis of CSS is generally good. with the introduction of 
corticosteroid treatment, remission and survival rates 
have improved greatly. Refractory CSS may be re-
sponsive to cyclophosphamide, azathioprine, or high-
dose intravenous immunoglobulins. 
The purpose of this case report is to indicate the im-
portance of early recognition of CSS and systemic vascu-
litis in patients with asthma and peripheral eosinophilia. 
The treatment should be targeted to prevent disease pro-
gression and its potentially fatal consequences.
Case Report
A 38-year-old man was admitted to the hospital 
because of an episode of syncope and an echocar-
diographic finding of subacute myopericarditis. two 
months before, he was hospitalized for seven days 
because of a pulmonary infiltrate in the lower left 
lobe. upon recovery, he was planned for elective na-
sal polypectomy. during routine preoperative testing, 
the patient reported malaise, generalized myalgia, oc-
casional night sweats, increasing exertional dyspnea, 
and nonproductive cough. An abnormal electrocar-
diogram (eCg) was found: sinus tachycardia, low 
QRS voltage, and invert t-waves in precordial leads. 
transthoracic echocardiogram (tte) detected a 
moderate reduction in global contractility, distal sep-
tal hypokinesis, and pericardial effusion of 500 to 700 
ml. laboratory studies revealed peripheral blood eo-
sinophilia (3.6x109/l), increased C-reactive  protein 
(89.0 mg/l), and elevated gammaglobulins (29.9%; 
igg 23.83 g/l), and the patient was transferred to our 
institution for further studies.
At admission, enquiry confirmed a history of 
chronic sinusitis and sinonasal polyposis for more 
than 10 years, and moderate persistent asthma for the 
last 4 years. Asthma was reasonably well controlled 
with regular use of a combination of salmeterol and 
fluticasone. on physical examination, the patient was 
mildly pyrexial but had no rashes or purpura. two 
small bilateral painful skin nodules on the scalp were 
noticed. heart sounds were muffled, otherwise nor-
mal finding. Respiratory examination revealed a mild 
diffuse bronchospasm. 
laboratory investigation revealed persistent pe-
ripheral eosinophilia. immunoassays for parasitic 
diseases (echinococcosis, amebiasis, trichinellosis, 
cysticercosis, toxocariasis, strongyloidiasis, leishma-
niasis, fascioliasis, and ascaridosis) were negative. 
Stool microscopy showed no abnormalities. in spite 
of negative immunoassays for parasitic infections, 
during initial hospitalization the patient was treated 
with albendazole (400 mg/day for 12 days). Current 
or past infection with cardiotrophic viral agents was 
not revealed. Antineutrophilic cytoplasmic antibod-
ies (AnCA) and antinuclear antibody (AnA) assays 
yielded negative results, while rheuma factor (RF), 
anti-citrullinated protein (CCp), anticardiolipin anti-
bodies (aCi-igg, aCi-igm), C3 and C4 components 
of complement were within the normal ranges. ige 
was elevated (345 kiu/l). pulmonary function tests 
confirmed an Fev1/FvC ratio of 3.27/4.88 (67%), 
suggesting a mild obstructive defect. Bone marrow 
and peripheral blood investigation revealed morpho-
logically normal hematopoiesis, and increased normal 
and mature eosinophils. The karyotype was normal. 
JAK2 v617F point mutation test and BCR-ABl 
p210 oncogene were negative. Fip1l1-pdgFR alfa 
fusion gene, a recurrent molecular lesion in idiopathic 
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hypereosinophilic syndrome, which makes a basis for 
the diagnosis of chronic eosinophilic leukemia was 
not detected. Fiberoptic bronchoscopy visualized nor-
mal bronchial lumen, diffusely inflamed bronchial 
mucosa, and moderate mucopurulent bronchial secre-
tion. Bronchoalveolar lavage (BAl) with 150 ml of 
warmed saline was performed. BAl cytology revealed 
eosinophilic alveolitis (30% of eosinophils in BAl 
fluid). in addition, nasal smear cytology revealed an 
increased number of eosinophils. electromyography 
finding was normal. Smears of the skin nodule biopsy 
revealed eosinophils and fat cells.
tte performed at admission detected moderate 
reduction in global contractility, distal septal hypoki-
nesis, and normal morphology of the valvular appara-
tus. pericardial effusion thickness, measured in diastole 
behind the right ventricle, was 14 mm (Fig. 1). Cardiac 
magnetic resonance imaging (CmRi), performed upon 
the resolution of pericardial effusion, demonstrated 
normal pericardial thickness, impaired contractility, 
especially of the distal septum, and paradoxical inter-
ventricular septal motion. Systolic left ventricular (lv) 
function was mildly impaired (lv end-diastolic volume 
150 ml, lv end-systolic volume 85 ml, and lv ejec-
tion fraction 43%). delayed post-contrast sequences 
Fig. 2. Contrast CMR imaging in systole (A) and diastole (B) reveals diffuse transmural and subendocardial delayed 
hyperenhancement in the basal septum and both ventricles with involvement of the papillary muscles (white arrows).
Fig. 1. M-mode echocardiogram of the left ventricle (LV) 
in the parasternal long-axis view: LVEF is reduced 
(45%-50%) due to IVS hypocontractility; slight hypertro-
phy of both IVS and posterior wall. Echo free space relates 
to the moderate effusion behind the LV through systole and 
diastole. 
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(gadolinium-based paramagnetic contrast agent) dem-
onstrated the presence of diffuse transmural contrast 
imbibition in the basal septum and subendocardial 
contrast enhancement in the septum, both ventricles, 
and papillary muscles. The type of diffuse contrast dis-
tribution indicated inflammation of the myocardium, 
while subendocardial imbibition related primarily to 
vasculitic lesions (Fig. 2).
The diagnosis of CSS was based on the patient’s 
history (late-onset asthma, chronic sinusitis, sinonasal 
polyposis), prominent eosinophilia (peripheral blood, 
bone marrow, skin nodules, lungs and nasal mucosa), 
and recent pulmonary infiltrates. The patient fulfilled 
5 out of 6 ARA classification criteria for CSS. tte 
and CmRi documented myopericardial involvement. 
The treatment with medium-dose oral methylpredni-
solone led to significant clinical improvement, rapid 
normalization of peripheral blood eosinophilia, and 
resolution of the pericardial effusion. 
Discussion
we present a patient with CSS with myopericar-
dial involvement. Since the initial report describing 
CSS, cardiac involvement has been considered com-
mon and given a high rank among the causes of mor-
bidity and mortality9. early studies reported that car-
diac failure had occurred in 47% and pericarditis in 
32% of all cases, the former disorder accounting for 
48% of deaths, most often due to myocardial infarc-
tion, malignant ventricular arrhythmias, heart failure, 
and cardiac tamponade10. 
during the last decade, cardiac complications of 
CSS have been studied more comprehensively, al-
though most often in relatively small series of patients 
or as case reports. using clinical evaluation, eCg, 
tte, CmRi, and endomyocardial biopsy, cardiac 
involvement was recently documented in 22 out of 49 
patients with CSS11. Cardiac presentations included 
impaired left ventricular function (50%), mild to se-
vere valvular insufficiencies (73%), pericardial effu-
sions (41%), and endomyocarditis (59%)11. using the 
same diagnostic tools, a high prevalence of cardiac in-
volvement (62%) was found even in patients with CSS 
in remission12. Clinical symptoms were present in only 
26% of patients, supporting the proposal that cardiac 
involvement in CSS may often be silent but poten-
tially of severe prognosis. in accordance with this, the 
clinical manifestations of myopericardial involvement 
in our patient were relatively mild and nonspecific. 
Recent studies underline the important role of 
CmRi in the assessment of myopericardial involve-
ment in CSS because of its potential to visualize 
various forms of inflammatory changes in the myo-
cardium11-14. in a series of 11 patients with biopsy-
proven CSS and clinical evidence of cardiac involve-
ment, systolic left ventricular function was impaired 
in 6 patients, edema was present in 4 cases, 7 pa-
tients had pericardial effusion, while late enhance-
ment lesions were detected in 9 of 11 patients14. it 
is especially important that these lesions could even 
be detected in patients with normal left ventricular 
size and function, where tte has limited diagnostic 
usefulness13,14. in addition, CmRi could be a useful 
tool for direct monitoring of myocardial response to 
medical treatment, independent of lv ejection frac-
tion or eCg abnormalities15. in our patient, CmRi 
also had a major clinical impact on the diagnosis of 
myocardial injury. together with mild impairment of 
lv systolic function, CmRi visualized myocardial 
perfusion defects most likely secondary to vasculitis 
of the small myocardial vasculature and myocardial 
infiltration.
Churg-Strauss syndrome has previously been re-
ported as being associated with antineutrophil cy-
toplasmic antibodies targeting myeloperoxidase 
(AnCA) in 39% to 59% of patients16,17. in a uniquely 
large cohort of 112 patients with CSS, followed for 
approximately 3 years and aimed to better define the 
clinical and biological characteristics of newly diag-
nosed CSS, the authors detected AnCA in 43 (38%) 
patients18. positive AnCA was associated with re-
nal involvement, peripheral neuropathy, and biopsy-
proven vasculitis, whereas negative AnCA status 
was associated with heart disease and fever18. This 
could mean that AnCA are probably more involved 
in the vasculitic manifestations of CSS (e.g., glom-
erulonephritis), whereas eosinophil tissue infiltration 
and associated cytotoxicity would be responsible for 
cardiomyopathy18,19. our data fit to this proposal, i.e. 
the CSS was AnCA-negative with high eosinophilia, 
eosinophilic alveolitis and cardiac involvement.
The cited findings, if confirmed, could support 
individual therapeutic stratification according to the 
clinical pattern. however, until then corticosteroids 
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and cyclophosphamide remain the foundation of CSS 
treatment1,20,21. The prognosis of CSS is generally good 
although it depends significantly on early initiation of 
treatment. According to the report of the european 
vasculitis Study group (euvAS), the remission rate 
was 81% to 91%, the 5-year survival was 60%-97%, 
and the relapse frequency in the first 2 years was 15% 
to 35%21.
in accordance to the proposed recommendation 
that mild to moderate forms of CSS could be treated 
with corticosteroids only20,21, our patient was treated 
with medium-dose methylprednisolone. After three 
weeks of treatment, significant clinical improvement 
together with tte-confirmed resolution of pericar-
dial effusion was observed. Cytotoxic drugs might 
be necessary in less than 20% of patients, mostly in 
those with major life-threatening organ involve-
ment. other tested treatments, especially in patients 
with refractory and steroid-dependent CSS, include 
interferon-alpha22, infliximab23, rituximab24, and few 
other approaches (plasmapheresis, anti-il5, and anti-
ige monoclonal antibodies)25. when discussing treat-
ment modalities, it should be noted that some con-
cerns have been raised that the treatment of asthma 
with leukotriene receptor antagonists may be associ-
ated with an increased incidence of CSS26. however, 
the causative role of antileukotrienes in CSS has not 
been confirmed. The current level of evidence sug-
gests that antileukotrienes, by reducing the need for 
oral corticosteroids, allow for the eosinophilic and 
particularly the vasculitic manifestations of CSS to be 
„unmasked“. Therefore, monitoring for the signs and 
symptoms of CSS is strongly recommended in asthma 
patients tapered off corticosteroids.
in conclusion, CSS is a rare but potentially fatal 
condition, which occurs in patients with late-onset 
asthma. Since clinical manifestations could be sub-
clinical in spite of significant damage of the affected 
organs, it is crucial to establish an accurate diagnosis 
and treat the patient as early as possible, thus prevent-
ing further disease progression. increased peripheral 
eosinophilia and transient pulmonary infiltrates may 
be the initial warnings. Cardiac damage is frequent, 
often silent initially and undetectable with standard 
cardiac imaging techniques, such as cardiac ultra-
sound or myocardial scintigraphy. CmR imaging 
permits early diagnosis of different types of cardiac 
involvement, and therefore should be part of the di-
agnostic algorithm. 
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Sažetak
ChuRg-StRAuSSov SindRom SA ZAhvAćenim miopeRiKARdom
Đ. Ljubičić, Z. Matković, N. Piskač-Živković i N. Tudorić
Churg-Straussov sindrom (CSS) je nekrotizirajući vaskulitis malih krvnih žila koji je znakovito obilježen astmom, 
plućnim infiltracijama, ekstravaskularnim nekrotizirajućim granulomima i hipereozinofilijom. Srčana bolest je najvaž-
niji uzrok smrti kod CSS. opisuje se 38-godišnji muškarac s astmom kasnog nastupa, alergijskim rinosinusitisom i vi-
sokom ekstravaskularnom i perifernom eozinofilijom, koji se prezentira s migrirajućim plućnim infiltratima i akutnim 
mioperikarditisom. Antineutrofilna citoplazmatska antitijela (AnCA) bila su negativna. Rana terapija srednjom dozom 
metilprednizolona riješila je perikardijalni izljev i dovela do značajnog kliničkog poboljšanja. u ovom prikazu slučaja 
raspravlja se o važnosti ranog prepoznavanja CSS kod bolesnika s astmom i perifernom eozinofilijom. uz elektro- i eho-
kardiografiju, magnetska rezonancija srca može pomoći u ranom otkrivanju zahvaćenosti srca kod CSS, te tako omogućiti 
primjereno liječenje kako bi se spriječilo napredovanje bolesti i moguće pogubne posljedice.
Ključne riječi: Churg-Straussov sindrom – komplikacije; Churg-Straussov sindrom – epidemiologija; Churg-Straussov sin-
drom – imunologija; Srčane bolesti – dijagnostika; Astma – imunologija; Prikaz slučaja
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